Author

M. L. Miller

Primary ORCID profile (0000-0002-6350-5706 · 1 paper)Unclaimed ORCID profile · follow to get notified of new preprints

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Same name, identified by ORCID

M. L. MilleriD1 paper · Columbia University

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Organism:human· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cell-cell communication· 1 Approach:machine learning (classical)· 1 Assay:whole-exome sequencing· 1

Frequent Co-Authors

A. Chow· 1 shared A. J. Minn· 1 shared A. J. Plodkowski· 1 shared A. J. Schoenfeld· 1 shared A. Jimenez-Sanchez· 1 shared A. Snyder· 1 shared A. Vargas· 1 shared B. D. Greenbaum· 1 shared

Activity by Year

2018-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Chow

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancer

D. Memon, H. Rizvi, G. Fromm, J. Lihm, A. J. Schoenfeld, J. L. Sauter, J. Luo, A. Chow, U. K. Bhanot, C. McCarthy, D. Ye, C. M. Vanderbilt, C. Liu, M. Abu-Akeel, A. J. Plodkowski, , M. D. Hellmann

This study characterizes clinical and molecular features of acquired resistance to PD-(L)1 blockade in NSCLC, identifying persistent inflammation and dysfunctional IFN signaling as key features.

bioRxiv · Jul 21, 2021Cancer Biology

Unraveling Tumor-Immune Heterogeneity in Advanced Ovarian Cancer Uncovers Immunogenic Effect of Chemotherapy

A. Jimenez-Sanchez, P. Cybulska, K. Lavigne, T. Walther, I. Nikolovski, Y. Mazaheri, B. Weigelt, D. S. Chi, K. J. Park, T. Hollmann, D.-L. Couturier, A. Vargas, J. D. Brenton, E. Sala, A. Snyder, M. L. Miller

This study analyzes tumor-immune heterogeneity in ovarian cancer before and after chemotherapy, finding that chemotherapy increases cytotoxic immune activation in site-matched samples.

bioRxiv · Oct 17, 2018Cancer Biology